Cambridge, MA
K36 Therapeutics mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies.
k36tx.comThese are collections K36 Therapeutics is a part of. Click on the collection name to view similar companies.
Series B
$70,000,000
Series A
$30,000,000
0 out of 5 stars
Based on 0 reviews
Worked here? Share your experience. Help others decide if this company is right for them. Write a review on K36 Therapeutics.